CTSO Stock - Cytosorbents Corporation
Unlock GoAI Insights for CTSO
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Free 14-day trial • No credit card required
Premium members get real-time SMS alerts
Financial Statements
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $35.59M | $31.08M | $34.69M | $40.11M | $39.45M |
| Gross Profit | $25.13M | $21.95M | $20.73M | $29.06M | $28.40M |
| Gross Margin | 70.6% | 70.6% | 59.8% | 72.5% | 72.0% |
| Operating Income | $-16,785,939 | $-31,948,620 | $-31,521,879 | $-22,744,745 | $-10,370,334 |
| Net Income | $-20,718,957 | $-29,246,760 | $-32,812,582 | $-24,558,648 | $-7,837,188 |
| Net Margin | -58.2% | -94.1% | -94.6% | -61.2% | -19.9% |
| EPS | $-0.38 | $-0.65 | $-0.75 | $-0.57 | $-0.20 |
Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology. Its flagship product is CytoSorb, an extracorporeal cytokine filter for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention and treatment of perioperative complications of cardiopulmonary bypass surgery, and maintaining or enhancing the quality of solid organs harvested from donors for organ transplant. The company also develops VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals; CytoSorb-XL, a device for adjunctive therapy in the treatment of sepsis and other critical illnesses; HemoDefend blood purification technology platform to reduce contaminants in the blood supply that can cause transfusion reactions or disease when administering blood and blood products to patients, as well as removal of anti-A and anti-B blood group antibodies from fresh whole blood and plasma; K+ontrol for treatment of severe hyperkalemia in patients with life-threatening conditions; and ContrastSorb for the removal of IV contrast in blood administered during CT imaging, an angiogram, or during a vascular interventional radiology procedure to reduce the risk of contrast-induced nephropathy. In addition, it is involved in the development of BetaSorb, a device for the prevention and treatment of health complications caused by the accumulation of metabolic toxins in patients with chronic renal failure; DrugSorb, a device to remove toxic chemicals from the blood; and DrugSorb-ATR, an antithrombotic removal system. The company was formerly known as MedaSorb Technologies Corporation and changed its name to Cytosorbents Corporation in May 2010. Cytosorbents Corporation was founded in 1997 and is headquartered in Princeton, New Jersey.
Visit WebsiteRating Distribution
Price Targets
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| September 7th 2023 | B. Riley Securities | Initiation | Buy | $4 |
Earnings History & Surprises
CTSOEPS Surprise History
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q4 2026 | Nov 3, 2026 | — | — | — | — |
Q3 2026 | Aug 10, 2026 | — | — | — | — |
Q1 2026 | Mar 30, 2026 | $-0.06 | — | — | — |
Q1 2026 | Jan 1, 2026 | — | — | — | — |
Q4 2025 | Nov 13, 2025 | $-0.06 | $-0.04 | +33.3% | ✓ BEAT |
Q3 2025 | Aug 7, 2025 | $-0.07 | $-0.05 | +28.6% | ✓ BEAT |
Q2 2025 | May 14, 2025 | $-0.08 | $-0.06 | +25.0% | ✓ BEAT |
Q1 2025 | Mar 31, 2025 | $-0.07 | $-0.03 | +57.1% | ✓ BEAT |
Q4 2024 | Nov 7, 2024 | $-0.07 | $-0.08 | -14.3% | ✗ MISS |
Q3 2024 | Aug 13, 2024 | $-0.09 | $-0.08 | +11.1% | ✓ BEAT |
Q2 2024 | May 9, 2024 | $-0.12 | $-0.12 | 0.0% | = MET |
Q1 2024 | Mar 14, 2024 | $-0.14 | $-0.12 | +14.3% | ✓ BEAT |
Q4 2023 | Nov 9, 2023 | $-0.12 | $-0.21 | -75.0% | ✗ MISS |
Q3 2023 | Aug 1, 2023 | $-0.11 | $-0.14 | -27.3% | ✗ MISS |
Q2 2023 | May 2, 2023 | $-0.13 | $-0.17 | -30.8% | ✗ MISS |
Q1 2023 | Mar 9, 2023 | $-0.17 | $-0.01 | +94.1% | ✓ BEAT |
Q4 2022 | Nov 3, 2022 | $-0.16 | $-0.28 | -75.0% | ✗ MISS |
Q3 2022 | Aug 2, 2022 | $-0.14 | $-0.25 | -78.6% | ✗ MISS |
Q2 2022 | May 3, 2022 | $-0.15 | $-0.21 | -40.0% | ✗ MISS |
Q1 2022 | Mar 8, 2022 | $-0.13 | $-0.21 | -61.5% | ✗ MISS |
Latest News
D. Boral Capital Maintains Buy on CytoSorbents, Maintains $10 Price Target
📈 PositiveHC Wainwright & Co. Maintains Neutral on CytoSorbents, Lowers Price Target to $0.75
➖ NeutralCytoSorbents Q3 Adj. EPS $(0.04) Beats $(0.05) Estimate, Sales $9.485M Miss $10.034M Estimate
➖ NeutralD. Boral Capital Maintains Buy on CytoSorbents, Maintains $10 Price Target
📈 PositiveCytoSorbents To Refile De Novo Application For DrugSorb-ATR, Expects FDA Review In Mid-2026
➖ NeutralD. Boral Capital Maintains Buy on CytoSorbents, Maintains $10 Price Target
📈 PositiveCytosorbents shares are trading lower after the company announced the FDA has upheld its denial for De Novo.
📉 NegativeCytoSorbents Updates FDA Status: Appeal Confirms No Safety Issues For DrugSorb-ATR But Upholds De Novo Denial; FDA Proposes Path Forward For Market Authorization
➖ NeutralFrequently Asked Questions about CTSO
What is CTSO's current stock price?
What is the analyst price target for CTSO?
What sector is Cytosorbents Corporation in?
What is CTSO's market cap?
Does CTSO pay dividends?
Similar Stocks
Healthcare SectorExplore stocks similar to CTSO for comparison